Cargando…
Carbon‐ion radiotherapy for oligometastatic liver disease: A national multicentric study by the Japan Carbon‐Ion Radiation Oncology Study Group (J‐CROS)
Reports on the therapeutic efficacy and safety of carbon‐ion radiotherapy (C‐ion RT) for oligometastatic liver disease are limited, with insufficient evidence. This study aimed to evaluate the clinical outcomes of C‐ion RT for oligometastatic liver disease at all Japanese facilities using the nation...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475754/ https://www.ncbi.nlm.nih.gov/pubmed/37391921 http://dx.doi.org/10.1111/cas.15871 |
_version_ | 1785100783753101312 |
---|---|
author | Shiba, Shintaro Wakatsuki, Masaru Toyama, Shingo Terashima, Kazuki Uchida, Hirofumi Katoh, Hiroyuki Shibuya, Kei Okazaki, Shohei Miyasaka, Yuhei Ohno, Tatsuya Tsuji, Hiroshi |
author_facet | Shiba, Shintaro Wakatsuki, Masaru Toyama, Shingo Terashima, Kazuki Uchida, Hirofumi Katoh, Hiroyuki Shibuya, Kei Okazaki, Shohei Miyasaka, Yuhei Ohno, Tatsuya Tsuji, Hiroshi |
author_sort | Shiba, Shintaro |
collection | PubMed |
description | Reports on the therapeutic efficacy and safety of carbon‐ion radiotherapy (C‐ion RT) for oligometastatic liver disease are limited, with insufficient evidence. This study aimed to evaluate the clinical outcomes of C‐ion RT for oligometastatic liver disease at all Japanese facilities using the nationwide cohort data. We reviewed the medical records to obtain the nationwide cohort registry data on C‐ion RT between May 2016 and June 2020. Patients (1) with oligometastatic liver disease as confirmed by histological or diagnostic imaging, (2) with ≤3 synchronous liver metastases at the time of treatment, (3) without active extrahepatic disease, and (4) who received C‐ion RT for all metastatic regions with curative intent were included in this study. C‐ion RT was performed with 58.0–76.0 Gy (relative biological effectiveness [RBE]) in 1–20 fractions. In total, 102 patients (121 tumors) were enrolled in this study. The median follow‐up duration for all patients was 19.0 months. The median tumor size was 27 mm. The 1‐year/2‐year overall survival, local control, and progression‐free survival rates were 85.1%/72.8%, 90.5%/78.0%, and 48.3%/27.1%, respectively. No patient developed grade 3 or higher acute or late toxicity. C‐ion RT is a safe and effective treatment for oligometastatic liver disease and may be beneficial as a local treatment option in multidisciplinary treatment. |
format | Online Article Text |
id | pubmed-10475754 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104757542023-09-05 Carbon‐ion radiotherapy for oligometastatic liver disease: A national multicentric study by the Japan Carbon‐Ion Radiation Oncology Study Group (J‐CROS) Shiba, Shintaro Wakatsuki, Masaru Toyama, Shingo Terashima, Kazuki Uchida, Hirofumi Katoh, Hiroyuki Shibuya, Kei Okazaki, Shohei Miyasaka, Yuhei Ohno, Tatsuya Tsuji, Hiroshi Cancer Sci ORIGINAL ARTICLES Reports on the therapeutic efficacy and safety of carbon‐ion radiotherapy (C‐ion RT) for oligometastatic liver disease are limited, with insufficient evidence. This study aimed to evaluate the clinical outcomes of C‐ion RT for oligometastatic liver disease at all Japanese facilities using the nationwide cohort data. We reviewed the medical records to obtain the nationwide cohort registry data on C‐ion RT between May 2016 and June 2020. Patients (1) with oligometastatic liver disease as confirmed by histological or diagnostic imaging, (2) with ≤3 synchronous liver metastases at the time of treatment, (3) without active extrahepatic disease, and (4) who received C‐ion RT for all metastatic regions with curative intent were included in this study. C‐ion RT was performed with 58.0–76.0 Gy (relative biological effectiveness [RBE]) in 1–20 fractions. In total, 102 patients (121 tumors) were enrolled in this study. The median follow‐up duration for all patients was 19.0 months. The median tumor size was 27 mm. The 1‐year/2‐year overall survival, local control, and progression‐free survival rates were 85.1%/72.8%, 90.5%/78.0%, and 48.3%/27.1%, respectively. No patient developed grade 3 or higher acute or late toxicity. C‐ion RT is a safe and effective treatment for oligometastatic liver disease and may be beneficial as a local treatment option in multidisciplinary treatment. John Wiley and Sons Inc. 2023-06-30 /pmc/articles/PMC10475754/ /pubmed/37391921 http://dx.doi.org/10.1111/cas.15871 Text en © 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | ORIGINAL ARTICLES Shiba, Shintaro Wakatsuki, Masaru Toyama, Shingo Terashima, Kazuki Uchida, Hirofumi Katoh, Hiroyuki Shibuya, Kei Okazaki, Shohei Miyasaka, Yuhei Ohno, Tatsuya Tsuji, Hiroshi Carbon‐ion radiotherapy for oligometastatic liver disease: A national multicentric study by the Japan Carbon‐Ion Radiation Oncology Study Group (J‐CROS) |
title | Carbon‐ion radiotherapy for oligometastatic liver disease: A national multicentric study by the Japan Carbon‐Ion Radiation Oncology Study Group (J‐CROS) |
title_full | Carbon‐ion radiotherapy for oligometastatic liver disease: A national multicentric study by the Japan Carbon‐Ion Radiation Oncology Study Group (J‐CROS) |
title_fullStr | Carbon‐ion radiotherapy for oligometastatic liver disease: A national multicentric study by the Japan Carbon‐Ion Radiation Oncology Study Group (J‐CROS) |
title_full_unstemmed | Carbon‐ion radiotherapy for oligometastatic liver disease: A national multicentric study by the Japan Carbon‐Ion Radiation Oncology Study Group (J‐CROS) |
title_short | Carbon‐ion radiotherapy for oligometastatic liver disease: A national multicentric study by the Japan Carbon‐Ion Radiation Oncology Study Group (J‐CROS) |
title_sort | carbon‐ion radiotherapy for oligometastatic liver disease: a national multicentric study by the japan carbon‐ion radiation oncology study group (j‐cros) |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475754/ https://www.ncbi.nlm.nih.gov/pubmed/37391921 http://dx.doi.org/10.1111/cas.15871 |
work_keys_str_mv | AT shibashintaro carbonionradiotherapyforoligometastaticliverdiseaseanationalmulticentricstudybythejapancarbonionradiationoncologystudygroupjcros AT wakatsukimasaru carbonionradiotherapyforoligometastaticliverdiseaseanationalmulticentricstudybythejapancarbonionradiationoncologystudygroupjcros AT toyamashingo carbonionradiotherapyforoligometastaticliverdiseaseanationalmulticentricstudybythejapancarbonionradiationoncologystudygroupjcros AT terashimakazuki carbonionradiotherapyforoligometastaticliverdiseaseanationalmulticentricstudybythejapancarbonionradiationoncologystudygroupjcros AT uchidahirofumi carbonionradiotherapyforoligometastaticliverdiseaseanationalmulticentricstudybythejapancarbonionradiationoncologystudygroupjcros AT katohhiroyuki carbonionradiotherapyforoligometastaticliverdiseaseanationalmulticentricstudybythejapancarbonionradiationoncologystudygroupjcros AT shibuyakei carbonionradiotherapyforoligometastaticliverdiseaseanationalmulticentricstudybythejapancarbonionradiationoncologystudygroupjcros AT okazakishohei carbonionradiotherapyforoligometastaticliverdiseaseanationalmulticentricstudybythejapancarbonionradiationoncologystudygroupjcros AT miyasakayuhei carbonionradiotherapyforoligometastaticliverdiseaseanationalmulticentricstudybythejapancarbonionradiationoncologystudygroupjcros AT ohnotatsuya carbonionradiotherapyforoligometastaticliverdiseaseanationalmulticentricstudybythejapancarbonionradiationoncologystudygroupjcros AT tsujihiroshi carbonionradiotherapyforoligometastaticliverdiseaseanationalmulticentricstudybythejapancarbonionradiationoncologystudygroupjcros |